Zynex reports Q3 EPS 7c, consensus 6c

Reports Q3 revenue $50.0M, consensus $50.83M. “In Q3 2024 we continued our steady growth in orders as we positioned the company for long-term profitable growth,” said CEO Thomas Sandgaard. “Positive cash flow remains strong and both revenue and earnings were within guidance for Q3…We recognized a gap in the market for a high-quality TENS device that meets the specific criteria for insurance reimbursement, and TensWave is our answer to that demand. It complements our flagship multi-modality device, the NexWave, where Interferential current is the main modality and driver of obtaining prescriptions. Looking ahead, we will continue to diversify our pain management revenue stream with the introduction of new therapy products. Aggressive promotion of products from our salesforce will ensure sustained profitable growth. In 2025, we should return to our normal top-line growth in our pain management division of approximately 20%. Taken together, we believe our strategy is positioning us to become the world’s premier provider of holistic, non-invasive approaches to pain management”.